New CMDh Q&A Document on the Implementation of the EU Falsified Medicines Directive
Recommendation
4 June 2025
Vienna, Austria
In March CMDh published a new Q&A document to provide further guidance on the implementation of the EU Falsified Medicines Directive. The title reads "CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive".
The answers confirm the very flexible, independent and phased in approach as preparation for the 2D Code and anti-tampering. How to deal with mock-ups and the different approaches in the Member States is discussed in several Q&As.
The document also indicates that the safety features can already be implemented, even if the respective variation application has not been approved. However, requests for variations should be submitted as early as possible.
The document finally confirms that everything related to the safety features on packaging has to be implemented until 9 February 2019
You can find the complete"CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive" here.
Related GMP News
31.07.2024Report on Trends in the Falsification of Medicines
11.06.2024Serialization - Version 21 of the Q&As on Safety Features
17.01.2024Ozempic Falsification also in the US
20.12.2023US Track & Trace Guidance on Verification Systems
07.12.2023Falsification of Ozempic Confirmed
18.10.2023Ozempic Falsifications: BfArM starts Investigation